Hebei Changshan Biochemical Pharmaceutical Co., Ltd.

SZSE:300255 Stock Report

Market Cap: CN¥16.1b

Hebei Changshan Biochemical Pharmaceutical Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Hao Cai

Chief executive officer

CN¥500.2k

Total compensation

CEO salary percentagen/a
CEO tenure1.6yrs
CEO ownershipn/a
Management average tenure3.4yrs
Board average tenure3.1yrs

Recent management updates

Recent updates

Is Hebei Changshan Biochemical Pharmaceutical (SZSE:300255) Using Too Much Debt?

Jan 05
Is Hebei Changshan Biochemical Pharmaceutical (SZSE:300255) Using Too Much Debt?

Calculating The Intrinsic Value Of Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SZSE:300255)

Oct 30
Calculating The Intrinsic Value Of Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SZSE:300255)

Subdued Growth No Barrier To Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SZSE:300255) With Shares Advancing 55%

Oct 08
Subdued Growth No Barrier To Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SZSE:300255) With Shares Advancing 55%

Hebei Changshan Biochemical Pharmaceutical (SZSE:300255) Is Carrying A Fair Bit Of Debt

Sep 30
Hebei Changshan Biochemical Pharmaceutical (SZSE:300255) Is Carrying A Fair Bit Of Debt

Pinning Down Hebei Changshan Biochemical Pharmaceutical Co., Ltd.'s (SZSE:300255) P/S Is Difficult Right Now

Jul 25
Pinning Down Hebei Changshan Biochemical Pharmaceutical Co., Ltd.'s (SZSE:300255) P/S Is Difficult Right Now

Is Hebei Changshan Biochemical Pharmaceutical (SZSE:300255) Using Too Much Debt?

May 27
Is Hebei Changshan Biochemical Pharmaceutical (SZSE:300255) Using Too Much Debt?

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SZSE:300255) May Have Run Too Fast Too Soon With Recent 25% Price Plummet

Apr 15
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SZSE:300255) May Have Run Too Fast Too Soon With Recent 25% Price Plummet

Hebei Changshan Biochemical Pharmaceutical Co., Ltd.'s (SZSE:300255) 30% Share Price Surge Not Quite Adding Up

Mar 01
Hebei Changshan Biochemical Pharmaceutical Co., Ltd.'s (SZSE:300255) 30% Share Price Surge Not Quite Adding Up

CEO

Hao Cai (49 yo)

1.6yrs

Tenure

CN¥500,200

Compensation

Ms. Hao Cai serves as General Manager of Hebei Changshan Biochemical Pharmaceutical Co., Ltd. since June 4 , 2023.

Leadership Team

NamePositionTenureCompensationOwnership
Hao Cai
General Manager1.6yrsCN¥500.20kno data
Xiaohua Yue
Deputy GM & CFO1.2yrsCN¥70.00kno data
Yunxia Sun
Deputy GM & Non-Independent Director3.4yrsCN¥500.60kno data
Zhihua Li
Deputy General Manager4.6yrsCN¥500.20k0.032%
CN¥ 5.1m
Qing Zhang
Deputy General Manager4.6yrsCN¥671.70kno data
Zhenggang Xie
Deputy GM & Directorno datano datano data

3.4yrs

Average Tenure

50yo

Average Age

Experienced Management: 300255's management team is considered experienced (3.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Yunxia Sun
Deputy GM & Non-Independent Director3.7yrsCN¥500.60kno data
Zhenggang Xie
Deputy GM & Director1.7yrsno datano data
Xiaodong Gao
Chairman of the Board16.3yrsCN¥1.00m0.17%
CN¥ 26.8m
Shuxuan Gao
Chairman of the Supervisory Board6.1yrsno datano data
Jinliang Wang
Non-Employee Supervisor8.3yrsno datano data
Deying Cao
Independent Director3.1yrsCN¥60.00kno data
Xiangjun Wang
Independent Director3.1yrsCN¥60.00kno data
Zuolin Wang
Independent Directorno dataCN¥60.00kno data
Jie Gao
Director1.1yrsno datano data
Zhenggang Qie
Non-Independent Directorless than a yearno datano data
Qingsong Zong
Non-Employee Supervisorless than a yearno datano data

3.1yrs

Average Tenure

52yo

Average Age

Experienced Board: 300255's board of directors are considered experienced (3.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 21:57
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jing QiangChina International Capital Corporation Limited
Xiaoyan WangChina Minzu Securities
Hai Zhu PengHuatai Research